Umoja Biopharma
VivoVec uses engineered lentiviral vectors for in vivo CAR-T. The disclosed pipeline includes CD22 UB-VV400/410 and BCMA×GPRC5D UB-VV500. IASO retains Greater China rights to the partnered CD22 programs; UB-VV111 is partnered with AbbVie. Trial registration and IND clearance do not establish efficacy.
Corporate information
- Company entity
- Umoja Biopharma
- Headquarters / principal office
- Seattle, Washington, United States ↗
- Founded
- 2019 (company-reported) ↗
- Ownership / capital status
- PrivatePrivately held; disclosed Series C financing ↗
- Official corporate reference
- https://www.umoja-biopharma.com/ ↗
- LinkedIn company page
- LinkedIn ↗ ↗
- Latest financing / award identified
- 2025-01-14 · Series C · US$100 million ↗
Verified historical financing, not a claim that no later financing occurred.
Profile review: 2026-11-04 · Fields retain their individual source dates. Undisclosed values are not zero; early or historical events do not establish the latest financing. Awards and acquisitions are distinguished from equity rounds.
Start with public sources and capability boundaries; company claims are not independent certification.
Ask AI ↗Public evidence snapshot
VivoVec uses engineered lentiviral vectors for in vivo CAR-T. The disclosed pipeline includes CD22 UB-VV400/410 and BCMA×GPRC5D UB-VV500. IASO retains Greater China rights to the partnered CD22 programs; UB-VV111 is partnered with AbbVie. Trial registration and IND clearance do not establish efficacy.
This profile is a research snapshot, not a company endorsement. Check original sources for current information.
Original sources
- Official corporate website audit
- Primary corporate profile / legal-entity disclosure
- Founding / incorporation disclosure — scope stated in field